- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01902784
The Surrogate Project (Surrogate Storytelling)
Surrogate Project - Aim 2: Pilot Randomized Controlled Trial
Research Protocol Abstract:
This is a phase II controlled trial (RCT) of a "storytelling" intervention compared to no treatment among surrogates who have participated in a decision to limit life-sustaining treatment in the ICU for an incapacitated loved one. Subjects will be sequentially assigned to "storytelling" (a facilitated elicitation of the experience 2-4 weeks after bereavement) or no treatment with follow up "monitoring of well-being". Subjects will receive print bereavement brochures at 1 week, and undergo telephone symptom assessment at 2-weeks, 3-months, and 6-months after bereavement.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Screening/Re-contact (1st phase)
Eligible patients will:
- lack decision-making capacity
- have a surrogate decision maker (family member or friend)
Eligible surrogates will:
- be 18 years of age or older
- self-identify as having primary decision-making authority for the patient
- live within approximately 50miles or less of the University of Pittsburgh
be able to conduct a 1hr interview in English
- Court-appointed power of attorney will be excluded, as they are not expected to experience the same emotional distress as a family member or friend of a critically ill patient.
For Assignment to Intervention/Control (2nd phase)
Eligible surrogates will:
- have previously given consent for study staff to follow their loved one's course in the hospital and to be re-contacted
- have participated in decision making about limitation of life-sustaining treatments (LST) for their loved one (ICU patient)
- have had their loved one (ICU patient) die in the hospital
Exclusion Criteria:
Screening/Re-contact
Ineligible patients will:
- be less than 18 years old
- prisoners
- be of other legal concern, such as malpractice
Ineligible surrogates will:
- be less than 18 years old
- be unable to complete a 1-hour interview and questionnaires in English
- For Assignment to Intervention/Control
Ineligible patients will:
- have fully and permanently regained decision-making capacity and therefore no longer require a surrogate to make treatment decisions
- be discharged from hospital alive
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Storytelling Interview
Participants assigned to receive the intervention will participate in an interview with a trained interventionist who will facilitate the telling of their 'story' - the personal experience they went through as a surrogate decision-maker for a loved one in the intensive care unit (ICU), who subsequently died after decisions were made to limit life-sustaining treatments (LST). These participants will be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient). |
|
No Intervention: Monitoring of well-being
Participants assigned to the Monitoring of well-being group will receive follow up phone calls from study staff and be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute referral to mental health services
Time Frame: 2-6 weeks after patient death (during or after participation in study intervention interview)
|
We will assess acute risk of self-harm (or harm to others) and subsequent required referrals to mental health crisis services in participants throughout the intervention interview. Trained clinicians conducting interviews will refer when needed and record the number of participants requiring this service. Less than 5% of participants requiring an acute mental health crisis referral will be considered acceptable and an indicator of study safety. |
2-6 weeks after patient death (during or after participation in study intervention interview)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Research approach rates (participant interest)
Time Frame: start of recruitment - 6 months
|
We will record the number of eligible surrogate decision makers who agree to be approached by a study staff member to hear about this research project, when asked by a member of their patient's clinical team.
These counts will be summarized to assess a percentage and rate of eligible surrogates who agree to research approach among those who are eligible.
|
start of recruitment - 6 months
|
Randomization
Time Frame: 2- 6 weeks after patient death
|
We will randomize participants who consent to participation in the 2nd portion of the study, after completion of a baseline questionnaire. Eligible participants will be randomized with equal numbers of participants in the intervention and control groups. Randomization of 30 eligible participants to the intervention group and 30 to the control will be considered successful and an indicator of study feasibility. |
2- 6 weeks after patient death
|
Experience of participation
Time Frame: 6 months (end of study participation)
|
We will ask participants to report their experience of study participation by asking them, "How did participation in this study make you feel?" Five (5) answer choices will be given: Much better, Better, Neither better nor worse, Worse, or Much worse. 10% or fewer participants reporting that the study made them feel 'Worse' or 'Much Worse' will be considered successful and an indicator of study acceptability. |
6 months (end of study participation)
|
Burdensomeness of participation
Time Frame: 6 months (end of study participation)
|
We will ask participants to report how burdensome they felt participation in this study was for them by asking whether they Strongly Agree, Agree, Neither agree nor disagree, Disagree, or Strongly disagree with this statement: "Participating in this study was burdensome." 10% or fewer participants reporting that the study was burdensome, with a response of 'Strongly Agree' or 'Agree' will be considered successful and an indicator of study acceptability. |
6 months (end of study participation)
|
Participation regret
Time Frame: 6 months (end of study participation)
|
We will ask participants to report if they regret participation in this study by asking whether they Strongly Agree, Agree, Neither agree nor disagree, Disagree, or Strongly disagree with this statement: "I wish I hadn't agreed to participate in the study." 10% or fewer participants reporting that they regret their participation in this study, with a response of 'Strongly Agree' or 'Agree' will be considered successful and an indicator of study acceptability. |
6 months (end of study participation)
|
enrollment rate
Time Frame: start of recruitment - end of study
|
We will assess enrollment rate by recording the number of eligible participants who consent to participate and do participate in the intervention or control. The rate of enrollment will compare the number in this consented, participating group with the overall number of eligible participants encountered. We will consider an enrollment rate greater than 60% to be successful and an indicator of study feasibility. |
start of recruitment - end of study
|
completion of intervention session
Time Frame: 2 - 6 weeks after patient death
|
We will record the number of eligible participants randomly assigned to the intervention session who complete the intervention session. We will calculate a rate of completion for the intervention session. A completion rate of 80% or greater will be considered successful and an indicator of study feasibility. |
2 - 6 weeks after patient death
|
follow up questionnaire completion
Time Frame: 3 months +/- 9 days
|
We will record the number of participants who complete the 3-month follow up questionnaire. A completion rate of 80% or greater will be considered successful and an indicator of study feasibility. |
3 months +/- 9 days
|
follow up questionnaire completion
Time Frame: 6 months +/- 18 days
|
We will record the number of participants who complete the 6-month follow up questionnaire. A completion rate of 70% or greater will be considered successful and an indicator of study feasibility. |
6 months +/- 18 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Limit missing data
Time Frame: throughout study
|
We will assess rates of missing data throughout data collection.
A rate of 5% or lower missing data will be considered acceptable.
|
throughout study
|
Participant distress after traumatic life event
Time Frame: 2-4 weeks after patient death (baseline questionnaire)
|
We will summarize range and distribution of participant distress after a traumatic life event with the Impact of Events Scale.
Because this is a pilot trial, we will not conduct formal tests of efficacy.
|
2-4 weeks after patient death (baseline questionnaire)
|
Participant distress after traumatic life event
Time Frame: 3 months after patient death
|
We will summarize range and distribution of participant distress after a traumatic life event with the Impact of Events Scale.
Because this is a pilot trial, we will not conduct formal tests of efficacy.
|
3 months after patient death
|
Participant distress after traumatic life event
Time Frame: 6 months after patient death
|
We will summarize range and distribution of participant distress after a traumatic life event with the Impact of Events Scale.
Because this is a pilot trial, we will not conduct formal tests of efficacy.
|
6 months after patient death
|
Participant anxiety symptoms
Time Frame: 2-4 weeks after patient death (baseline questionnaire)
|
We will summarize range and distribution of participant anxiety symptoms with the Hospital Anxiety and Depression Scale (HADS). Because this is a pilot trial, we will not conduct formal tests of efficacy. |
2-4 weeks after patient death (baseline questionnaire)
|
Participant anxiety symptoms
Time Frame: 3 months after patient death
|
We will summarize range and distribution of participant anxiety symptoms with the Hospital Anxiety and Depression Scale (HADS). Because this is a pilot trial, we will not conduct formal tests of efficacy. |
3 months after patient death
|
Participant anxiety symptoms
Time Frame: 6 months after patient death
|
We will summarize range and distribution of participant anxiety symptoms with the Hospital Anxiety and Depression Scale (HADS). Because this is a pilot trial, we will not conduct formal tests of efficacy. |
6 months after patient death
|
Participant depression symptoms
Time Frame: 2-4 weeks after patient death (baseline questionnaire)
|
We will summarize range and distribution of participant depression symptoms with the Hospital Anxiety and Depression Scale (HADS) and the Primary Care Evaluation of Mental Disorders: Patient Health Questionnaire (PRIME-MD PHQ-9). Because this is a pilot trial, we will not conduct formal tests of efficacy. |
2-4 weeks after patient death (baseline questionnaire)
|
Participant depression symptoms
Time Frame: 3 months after patient death
|
We will summarize range and distribution of participant depression symptoms with the Hospital Anxiety and Depression Scale (HADS) and the Primary Care Evaluation of Mental Disorders: Patient Health Questionnaire (PRIME-MD PHQ-9). Because this is a pilot trial, we will not conduct formal tests of efficacy. |
3 months after patient death
|
Participant depression symptoms
Time Frame: 6 months after patient death
|
We will summarize range and distribution of participant depression symptoms with the Hospital Anxiety and Depression Scale (HADS) and the Primary Care Evaluation of Mental Disorders: Patient Health Questionnaire (PRIME-MD PHQ-9). Because this is a pilot trial, we will not conduct formal tests of efficacy. |
6 months after patient death
|
Complicated grief symptoms
Time Frame: 6 months (+/- 3 weeks) after patient death
|
We will assess whether surrogate participants are experiencing symptoms of complicated grief through administration of the Inventory of Complicated Grief during the final follow-up questionnaire at 6 months.
Responses will be summarized to better understand how this population may be experiencing symptoms of complicated grief.
|
6 months (+/- 3 weeks) after patient death
|
Subjective Units of Distress
Time Frame: 2-6 weeks after patient death (during & after completion of study intervention interview)
|
We will ask participants to rate their present level of distress with the Subjective Units of Distress Scale (SUDS) based on a scale of 0-100, where 0 is absolutely calm and 100 is the worst distress imaginable, during and after their participation in the study intervention interview. Less than 20% of participants experiencing very high levels of distress (SUDS > 70) after the interview will be considered successful and an indicator of acceptable safety. Note: This is a projected level of acceptability with a subjective measure. Our multidisciplinary team will continue to evaluate the safety of participation throughout study. |
2-6 weeks after patient death (during & after completion of study intervention interview)
|
Decision regret
Time Frame: 6 months (+/- 3 weeks) after patient death
|
We will assess whether surrogate participants are experiencing regret over their decisions in the Intensive Care Unit (ICU) for their deceased loved one through administration of the Decision Regret Scale during the final follow-up questionnaire at 6 months.
Responses will be summarized to better understand how this population may be experiencing symptoms of complicated grief.
|
6 months (+/- 3 weeks) after patient death
|
Decision regret
Time Frame: 3 months (+/- 3 weeks) after patient death
|
We will assess whether surrogate participants are experiencing regret over their decisions in the Intensive Care Unit (ICU) for their deceased loved one through administration of the Decision Regret Scale.
Responses will be summarized to better understand how this population may be experiencing symptoms of complicated grief.
|
3 months (+/- 3 weeks) after patient death
|
Decision regret
Time Frame: 2-4 weeks after patient death (baseline questionnaire)
|
We will assess whether surrogate participants are experiencing regret over their decisions in the Intensive Care Unit (ICU) for their deceased loved one through administration of the Decision Regret Scale.
Responses will be summarized to better understand how this population may be experiencing symptoms of complicated grief.
|
2-4 weeks after patient death (baseline questionnaire)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PRO13040209
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surrogate Decision Maker, After Death of Patient
-
University of ZurichCompletedPalliative Patients | Surrogate Decision MakerSwitzerland
-
Taipei Medical UniversityCompletedShared Decision Making | Quality of Care | Patient Decision Aids | Evidence-based Medicine | Lumbar Degenerative DiseaseTaiwan
-
University of Colorado, DenverNational Institute on Aging (NIA)CompletedHospice | Hospice Decision Making | End-of-life Decision MakingUnited States
-
Moroccan Society of SurgeryCompletedDecision Making | Quality of Health Care | Patient Care Team | Neoplasms/TherapyMorocco
-
Université de SherbrookeCompletedUncontrolled Donation After Circulatory Determination of Death
-
Brigham and Women's HospitalVanderbilt UniversityCompletedEnd of Life | Shared Decision MakingUnited States
-
University of MinnesotaNational Institute of Nursing Research (NINR)CompletedAdvance Care Planning | End of Life Decision MakingUnited States
-
Universitaire Ziekenhuizen KU LeuvenCompletedCondition of Patient 3 Years After FESS-operationBelgium
-
University of WashingtonCompletedEnd Stage Renal Disease | Patient Engagement | Dialysis | Decision Aid | End-of-life CareUnited States
-
Royal Victoria Hospital, CanadaRoyal Victoria Foundation; AlectraNot yet recruitingEnd of Life | Patient Preference | Goals of Care
Clinical Trials on Storytelling Interview
-
Institute of Population, Health and Development...University of Massachusetts, WorcesterCompleted
-
Istituto Auxologico ItalianoEuropean UnionCompleted
-
University of Colorado, DenverNational Institute of Nursing Research (NINR)CompletedHeart Failure | Cancer | COPDUnited States
-
Arizona State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingHealth Knowledge, Attitudes, Practice | COVID-19 Pandemic | Vaccine-Preventable Diseases | Health-Related Behavior | NarrationUnited States
-
Vanderbilt University Medical CenterFriends in Global HealthActive, not recruitingHIV InfectionsMozambique
-
University Hospital FreiburgStanford University; Heidelberg UniversityNot yet recruitingPsychological Capital
-
Mayo ClinicHennepin Healthcare Research Institute; Mountain Park Health CenterCompleted
-
University of Alabama at BirminghamVanderbilt University Medical CenterRecruiting
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Hennepin... and other collaboratorsCompletedType2 DiabetesUnited States